Achalasia Treatment Market
Achalasia Treatment Market Study by Non-surgical and Surgical in Hospitals, Specialty Clinics, and Research Institutes From 2024 to 2034
Analysis of Achalasia Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Achalasia Treatment Market Outlook (2024 to 2034)
The global achalasia treatment market is valued at US$ 472.12 million in 2024, as opined in the new market report by Fact.MR. The global market is forecasted to expand at a CAGR of 9.1% to reach US$ 1.13 billion by the end of 2034.
Chest discomfort, weight loss, heartburn, regurgitation, coughing at night, dysphagia, and postprandial aspiration are some of the symptoms of achalasia. The most prevalent symptom among achalasia sufferers is dysphagia. The reasons for achalasia are currently unknown. Oesophageal peristalsis anomalies are linked to achalasia. Treatment for achalasia is clearing blockages brought on by the lower oesophageal sphincter muscle's inability to relax. Achalasia sufferers find some respite from their condition with the use of medications, such as nifedipine or isosorbide.
Pneumatic balloon dilation, a technique that enlarges the lower oesophageal sphincter muscle, is considered a more successful treatment for around 70% of instances of achalasia. Adults with achalasia often range in age from 25 to 60. However, it is prone to occur at any age, including childhood. Achalasia's symptoms develop gradually. People suffering from achalasia are considered to be at the risk of acquiring oesophageal cancer.
The market for achalasia treatments is growing because of several important causes. The quick uptake of new technologies that boost productivity, save expenses, and raise the caliber of goods and services is one of the main causes. Thanks to this technological revolution, businesses now develop more quickly and satisfy changing customer needs.
Growth is also attributed to the opening up of new markets and client bases brought about by globalization and the improved connection it offers. However, there are some difficulties in the market. Regulatory barriers are major hindrances to market entrants and growth, particularly in areas with strict compliance requirements. Furthermore, shifting economic conditions influence consumer spending and investment levels, which in turn affects the market.
| Report Attributes | Details |
|---|---|
| Achalasia Treatment Market Size (2024E) | US$ 472.12 Million |
| Forecasted Market Value (2034F) | US$ 1.13 Billion |
| Global Market Growth Rate (2024 to 2034) | 9.1% CAGR |
| North America Market Value (2024E) | US$ 171.61 Million |
| Mexico Market Value (2034F) | US$ 27.51 Million |
| Hospital Segment Growth Rate (2024 to 2034) | 9.4% CAGR |
| Canada Market Value (2034F) | US$ 58.06 Million |
| Key Companies Profiled | Bristol-Myers; Squibb Company; Merck & Co; Eli Lilly and Company; AstraZeneca plc; Merz Therapeutics; Galderma; Zydus; AdvaCare Pharma. |
The demand for achalasia treatment experienced a major rise owing to an emergent need to focus on the health and well-being of people. In 2021, well-recognized manufacturers are investing in research and development projects to come up with advanced next-generation treatment procedures and drugs to ensure the fastest recovery.
Prominent players including Aesculap Corporation, Silex Medical, Teva Pharmaceuticals, Bausch Health, Osmotica Pharmaceuticals PLC, Pfizer Incorporation, and Mylan NV are focusing on the development of cost-effective and advanced treatments for ensuring the fastest recovery rates among the patients suffering from achalasia. They are making investments in research and development activities to deliver innovation in medical facilities and procedures.
For instance, Pzifer Corporation announced its latest introduction on 25th August 2020 for treating patients suffering from achalasia. The drug is named ‘NCT00066716’ which is a combination of celecoxib, paclitaxel, and carboplatin. Celecoxib may increase the effectiveness of chemotherapy drugs by making tumor cells more sensitive to the drug and also stop the growth of tumor cells by stopping blood flow to the tumor and blocking the enzymes necessary for their growth.
A combination of celecoxib with paclitaxel and carboplatin before surgery may shrink the tumor so that it is removed during surgery. The drug is currently undergoing phase II trials to identify how well the combination works in treating patients who are undergoing surgeries for esophageal cancer. Pzifer has made the drug available across the world to expand its business and improve its global presence.
In addition to Pzifer Corporation, Sanofi Corporation announced that the FDA has granted ‘Dupixent’ breakthrough therapy designation for eosinophilic esophagitis. Dupixent has become the first and only biologic to show positive and clinically meaningful phase 3 results in patients from 12 years and even older with eosinophilic esophagitis (EoE). There are currently no FDA-approved treatments for the chronic type 2 inflammatory disease damaging the esophagus except dupixent.
Patients treated weekly with dupixent 300 mg over a 24-week treatment period experienced a reduction in symptoms, esophageal inflammation, and abnormal endoscopic findings in the esophagus. The trial demonstrated safety results consistent with the known safety profile of dupixent in its approved indications. The EoE trial is ongoing with additional patients enrolling in part B as well as patients continuing in a 28-week extended active treatment period after completion of part A or part B.
Breakthrough therapy is designed with the aim of expediting the development and review of drugs that target serious conditions. Drugs qualifying for this designation must show preliminary clinical evidence that it may demonstrate a substantial endpoint over available therapies or over placebo if there are no available therapies. The potential use of dupixent in eosinophilic esophagitis is currently under clinical development.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Pneumatic Dilation Treatment to Gain Significant Traction in Achalasia Treatment Market
An increasing number of patients in medical centers demanding safe non-surgical treatments is expected to drive the demand for pneumatic dilation achalasia treatment. In addition, growing demand for the fastest and simplest technique is likely to further drive the demand for pneumatic dilation achalasia treatment.
Low-risk and cost-effectiveness associated with pneumatic dilation are likely to offer growth opportunities for the achalasia treatment market. A single session of the pneumatic dilation achalasia treatment is expected to provide relief for nearly seven years and follow-up is done as and when necessary. Women and older patients are witnessed as being majorly benefitted from pneumatic dilation achalasia treatment across the globe.
Demand for POEM (Peroral Endoscopic Myotomy) to Take an Upsurge
The major factor driving the demand for POEM achalasia treatment is minimal patient discomfort and quicker recovery. In addition, POEM achalasia treatment helps in eliminating scars' visibility, improves quality of life, and eliminates the concern regarding hernias, which are likely to form at the laparoscopic incision sites.
Specialty clinics are likely to contribute on a major basis towards revenue growth of the achalasia treatment market with an increasing number of cases amongst children. Key players and manufacturers in the achalasia treatment market are focusing on developing unmatched diagnostic tests with innovative treatments.
Across the globe, approximately 5% of the global population is suffering from a rare disorder, which makes the treatment of rare disorders a deliberating concern. Achalasia is a rare disorder of the esophagus that is generally characterized by the incomplete relaxation of the lower oesophageal sphincter in response to swallowing.
The symptoms of achalasia include chest pain, weight loss, heartburn, regurgitation, nocturnal coughing, dysphagia, and postprandial aspiration, among others. Dysphagia is the most common symptom in patients suffering from achalasia. The causes of achalasia are still unknown. Achalasia is associated with abnormalities of oesophageal peristalsis. Achalasia treatment involves the removal of obstructions caused because the lower oesophageal sphincter muscle fails to relax.
Drugs such as isosorbide or nifedipine provide some relief to patients suffering from achalasia. It is estimated that approximately 70% of achalasia cases are more effectively treated by the enlargement of the lower oesophageal sphincter muscle through a procedure known as pneumatic balloon dilation.
Achalasia generally affects adults aged between 25 and 60 years. However, it is likely to occur at any age, including childhood. The symptoms of achalasia appear gradually. People suffering from achalasia are expected to be at the risk of developing oesophageal cancer.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Achalasia Treatment Market: Drivers and Restraints
Increasing research grants and R&D expenditures from governments are driving the growth of the global achalasia treatment market. Rising government support is encouraging the development of treatment options for achalasia and is expected to change the landscape of achalasia treatment over the forecast period (2018 to 2028).
Furthermore, the presence of a small number of affected people is likely to put a severe strain on the healthcare system. Rare disorders are supported by well-organized patient advocacy organizations such as the National Organization for Rare Disorders (NORD).
However, inadequate treatment information about achalasia among healthcare providers is expected to restrain the global achalasia treatment market. In addition, awareness and understanding of rare disorders such as achalasia are often low and several patients are struggling to find adequate information about it. These factors are also expected to hamper the growth of the global achalasia treatment market.
Achalasia Treatment Market: Overview
Over the forecast period, the achalasia treatment market is expected to witness moderate growth. Approximately 85-90% of achalasia cases are treated with surgical procedures. During surgical procedures, the muscle fibers in the lower oesophageal sphincter are cut.
Among surgical treatment types, the Heller Myotomy segment is expected to lead in the global achalasia treatment market over the forecast period. The hospital end-user segment is expected to contribute to the maximum market share in the global achalasia treatment market. Achalasia treatment for patients majorly focuses on the improvement of symptoms.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Achalasia Treatment Market: Regional Outlook
Geographically, the global achalasia treatment market is segmented into North America, Latin America, Europe, Asia-Pacific excluding Japan (APEJ), Japan, and the Middle East and Africa (MEA). North America is expected to continue to dominate the global achalasia treatment market owing to the presence of prominent key players and favorable reimbursement scenarios in the region.
The Asia Pacific achalasia treatment market is expected to grow at a maximum CAGR over the forecast period due to the entry of new players in the region and increasing awareness about achalasia treatment. The Middle East & Africa and Latin America regions are expected to hold a minimum market share in the global achalasia treatment market owing to a lack of strategies for access to treatments for achalasia.
Achalasia Treatment Market: Key Players
Some of the key players operating in the global achalasia treatment market are Allergan plc; Ipsen Biopharmaceuticals, Inc.; Nestlé Skin Health (Galderma S.A.); Merz Pharma; Aesculap, Inc. and Silex Medical, LLC.
The report is a compilation of first-hand information, qualitative and quantitative assessments by industry analysts, and inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macroeconomic indicators, and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The report covers an exhaustive analysis on
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Technology
- Value Chain
Regional analysis includes
- North America (U.S., Canada)
- Latin America (Mexico, Brazil)
- Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
- Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
- Asia Pacific Excluding Japan (China, India, Australia & New Zealand)
- Japan
- Middle East and Africa (GCC, S. Africa, Rest Of MEA)
Report Highlights
- Detailed overview of the parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current, and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint.
Segmentation of the Achalasia Treatment Market
-
By Treatment :
- Non-surgical Treatment
- Surgical Treatment
-
By End User :
- Hospitals
- Specialty Clinics
- Research Institutes
-
By Region :
- North America
- Western Europe
- Eastern Europe
- Latin America
- East Asia
- South Asia & Pacific
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Industry Introduction, including Taxonomy and Market Definition
- 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
- 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections
- 5. Pricing Analysis
- 6. Global Market Analysis and Forecast
- 7. Global Market Analysis and Forecast, By Treatment
- 7.1. Non-Surgical Treatment
- 7.2. Surgical Treatment
- 8. Global Market Analysis and Forecast, By End User
- 8.1. Hospitals
- 8.2. Specialty Clinics
- 8.3. Research Institutes
- 9. Global Market Analysis and Forecast, By Region
- 9.1. North America
- 9.2. Latin America
- 9.3. Western Europe
- 9.4. Eastern Europe
- 9.5. East Asia
- 9.6. South Asia & Pacific
- 9.7. MEA
- 10. North America Sales Analysis and Forecast, by Key Segments and Countries
- 11. Latin America Sales Analysis and Forecast, by Key Segments and Countries
- 12. Western Europe Sales Analysis and Forecast, by Key Segments and Countries
- 13. Eastern Europe Sales Analysis and Forecast, by Key Segments and Countries
- 14. East Asia Sales Analysis and Forecast, by Key Segments and Countries
- 15. South Asia & Pacific Sales Analysis and Forecast, by Key Segments and Countries
- 16. MEA Sales Analysis and Forecast, by Key Segments and Countries
- 17. Sales Forecast by Treatment and End User for 30 Countries
- 18. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
- 19. Company Profile
- 19.1. Allergan plc
- 19.2. Ipsen Biopharmaceuticals Inc.
- 19.3. Nestlé Skin Health (Galderma S.A.)
- 19.4. Merz Pharma
- 19.5. Aesculap, Inc.
- 19.6. Silex Medical LLC
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Global Market US$ Mn Forecast by Region
Table 2: Global Market US$ Mn Forecast by Treatment
Table 3: Global Market US$ Mn Forecast by End User
Table 4: North America Market US$ Mn Forecast by Country
Table 5: North America Market US$ Mn Forecast by Treatment
Table 6: North America Market US$ Mn Forecast by End User
Table 7: Latin America Market US$ Mn Forecast by Country
Table 8: Latin America Market US$ Mn Forecast by Treatment
Table 9: Latin America Market US$ Mn Forecast by End User
Table 10: Western Europe Market US$ Mn Forecast by Country
Table 11: Western Europe Market US$ Mn Forecast by Treatment
Table 12: Western Europe Market US$ Mn Forecast by End User
Table 13: Eastern Europe Market US$ Mn Forecast by Country
Table 14: Eastern Europe Market US$ Mn Forecast by Treatment
Table 15: Eastern Europe Market US$ Mn Forecast by End User
Table 16: East Asia Market US$ Mn Forecast by Country
Table 17: East Asia Market US$ Mn Forecast by Treatment
Table 18: East Asia Market US$ Mn Forecast by End User
Table 19: South Asia & Pacific Market US$ Mn Forecast by Country
Table 20: South Asia & Pacific Market US$ Mn Forecast by Treatment
Table 21: South Asia & Pacific Market US$ Mn Forecast by End User
Table 22: MEA Market US$ Mn Forecast by Country
Table 23: MEA Market US$ Mn Forecast by Treatment
Table 24: MEA Market US$ Mn Forecast by End User
Table 25: Latin America Market US$ Mn Forecast by Country
Table 26: Latin America Market US$ Mn Forecast by Treatment
Table 27: Latin America Market US$ Mn Forecast by End User
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 1: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Treatment
Figure 2: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 3: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Region
Figure 4: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Treatment
Figure 5: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 6: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 7: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Treatment
Figure 8: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 9: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 10: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Treatment
Figure 11: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 12: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 13: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Treatment
Figure 14: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 15: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 16: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Treatment
Figure 17: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 18: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 19: South Asia & Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Treatment
Figure 20: South Asia & Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 21: South Asia & Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 22: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Treatment
Figure 23: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 24: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 25: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Treatment
Figure 26: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 27: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How much is the achalasia treatment market likely to register during the forecast period?
The achalasia treatment market is analyzed to record a CAGR of 9.1% during the forecast period.
Why achalasia treatment market have high growth potential?
The market is growing with technological advancements, rising healthcare costs, and awareness of disease symptoms.
Where will manufacturers find the most opportunities in the achalasia treatment market?
The manufacturers of the achalasia treatment are finding the most opportunities in the North American region.
Achalasia Treatment Market